Hormonal
Long-term adherence to GLP-1 receptor agonist therapy significantly reduces the risk of major adverse liver outcomes (MALO) in patients with chronic liver disease and type 2 diabetes, whereas intention-to-treat analysis shows no significant benefit due to high discontinuation rates.
If you have chronic liver disease and type 2 diabetes, GLP-1 medications (like semaglutide or liraglutide) can significantly lower your risk of serious liver complications (like cirrhosis or liver cancer) over 10 years, BUT only if you keep taking them. Half of the patients in this study stopped taking the drug, which erased the benefit in the general group. To get the liver protection, you must manage side effects and stay on the treatment long-term.
In patients with chronic liver disease and type 2 diabetes who adhered to therapy over time, GLP1 agonists may result in lower risk of MALO... The risk of MALO was 49% lower in initiators of GLP1 agonists in the per- protocol analysis, but our data were not compatible with a protective intention- to- treat effect.
Why this rating
Observational emulation of a target trial using Swedish registers; strong causal inference methods but not a randomized controlled trial.
Source
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Axel Wester et al. · Gut · 2024
DOI 10.1136/gutjnl-2023-330962
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →